Low-Intensity Shockwave Therapy
Li-ESWT / GAINSWave, The Neovascularization Claim, the Sham RCTs, and the Focused-vs-Radial Bait-and-Switch
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved for ED (investigational; AUA/EAU)
Reference only. Not medical advice.
What can go wrong
Li-ESWT is generally low-risk: transient mild discomfort, penile numbness or petechiae, rarely bruising. The main harms are financial and the opportunity cost of pursuing an investigational therapy in place of a full workup for the vascular, hormonal, or psychological drivers of ED. There is no evidence it enlarges the penis or improves erections in men without underlying vascular ED.
This is something to take to a clinician. The Atlas can tell you what is known about low-intensity shockwave therapy in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Low-intensity extracorporeal shockwave therapy (Li-ESWT) applies focused acoustic pressure waves to the corpora cavernosa at an energy far below the level used to fracture kidney stones. The proposed mechanism is mechanotransduction: shear stress upregulating VEGF and endothelial nitric oxide synthase, recruiting endothelial progenitor cells, and driving neovascularization. Vardi's 2012 double-blind sham-controlled trial (J Urol 2012;187:1769-75, n=67) was the landmark demonstrating benefit over sham in men with vasculogenic ED. Subsequent meta-analyses show a statistically significant but modest, heterogeneous short-term improvement in IIEF-EF. The AUA (2018) and EAU classify it as investigational. Two honesty problems dominate: benefit often wanes by 6-12 months, and the radial (unfocused) devices sold in many US cash-pay clinics are physically different from the focused devices used in most positive trials.
The most-studied regenerative ED therapy, and the one whose marketing most abuses that fact.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Acoustic waves create localized mechanical shear stress and microcavitation in cavernosal tissue. Preclinical work from Yoram Vardi's group at Rambam (Haifa) proposed this triggers mechanotransduction cascades: upregulation of VEGF and eNOS, recruitment of endothelial progenitor cells and Schwann cells, and angiogenesis. Unlike PDE5 inhibitors, which act on demand, Li-ESWT is claimed to modify the underlying vascular disease. That disease-modifying claim is the part not durably confirmed in humans.
The catch: heterogeneity and the focused-vs-radial substitution
Meta-analyses (e.g., Sokolakis & Hatzichristodoulou 2019, and later pooled reviews) report a pooled IIEF-EF improvement that is statistically significant but of modest, sometimes sub-clinical magnitude, with high heterogeneity (I-squared frequently above 70%). Trials differ on energy flux density, total pulses, number of sessions, treatment sites, device type, and follow-up. Crucially, radial (pneumatic, unfocused) pressure-wave devices common in US cash-pay clinics are a different physical technology from the focused electrohydraulic/electromagnetic devices used in most positive RCTs, yet are marketed interchangeably as 'shockwave.' Effect tends to wane by 6-12 months in several studies, and long-term durability data are thin.
What people get wrong
Often saidGAINSWave and clinic shockwave are the same as the trial devices
ActuallyMany US clinics use radial/pneumatic units. Most positive RCTs used focused electrohydraulic or electromagnetic devices. The marketing rarely distinguishes them.
Often saidThe FDA cleared shockwave for ED
ActuallyThe FDA has not approved Li-ESWT for ED. Devices may be cleared for other uses; ED use is investigational per the AUA.
Often saidShockwave permanently cures ED and adds size
ActuallyBenefit is modest and often wanes within a year in responders, and there is no controlled evidence of any size increase.
Who profits, and who pushes back
AUA ED Guideline Panel
Li-ESWT should be considered investigational; insufficient evidence exists to recommend for or against its use for ED.
Revenue accrues to device manufacturers, the GAINSWave-style provider networks that sell branding and leads, and clinics billing cash for multi-session packages. Because sessions are unregulated in pricing and volume-driven, the incentive is to sell packages rather than to demonstrate durability.
What we do not know
- What focused-device protocol (energy, pulses, sessions) is optimal, and is any durable beyond a year?
- How much of the observed benefit is placebo, given the strong sham response in ED trials?
- Do radial devices produce any of the biological effect seen with focused devices?
At a glance
- Landmark trial
- Vardi 2012, J Urol, n=67, sham-controlled
- Energy density
- ~0.09-0.25 mJ/mm2 (low-intensity)
- AUA 2018
- Investigational
- Durability
- Often wanes by 6-12 months
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Low-Intensity Shockwave Therapy. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Vardi et al., J Urol (first double-blind sham-controlled Li-ESWT RCT)2012
n=67; significant improvement in erectile function and penile hemodynamics vs sham in vasculogenic ED, some benefit sustained to 6 months
Sokolakis & Hatzichristodoulou systematic review/meta-analysis2019
Pooled significant IIEF-EF benefit across RCTs but with high heterogeneity and protocol variability